The United States FDA will convene an expert panel to review the seasonal influenza vaccine from Moderna. The agency previously rejected the mRNA-based shot in February but reversed course after discussions with the company. A final approval decision is expected by August 5.
FDA to review Moderna mRNA flu vaccine on June 18
The FDA will convene an expert panel on June 18 to evaluate Moderna's mRNA-based flu vaccine. A final decision on the experimental shot is expected by August 5.
Xurve View
Insights:
Xurve View










